CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Phase 1/2 Recruiting
152 enrolled
IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL
Phase 1/2 Recruiting
30 enrolled
Pre-malignant States to Hematologic Malignancies in Firefighters
Recruiting
300 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Phase 2 Recruiting
30 enrolled
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Recruiting
100 enrolled
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia
Phase 1 Recruiting
24 enrolled
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Recruiting
500 enrolled
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
20 enrolled
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Phase 2 Recruiting
30 enrolled
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Phase 1/2 Recruiting
308 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
36 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
99,999 enrolled
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Recruiting
2,000 enrolled
MK-1026-003
Phase 2 Recruiting
490 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
439 enrolled
EXCELL
Phase 3 Recruiting
386 enrolled
CABAL2
Phase 1 Recruiting
90 enrolled
EPCOREâ„¢FL-2
Phase 3 Recruiting
1,095 enrolled
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Phase NA Recruiting
24 enrolled
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 Recruiting
18 enrolled
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Phase 1 Recruiting
130 enrolled
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Phase 1 Recruiting
24 enrolled
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Recruiting
1,263 enrolled
Tissue Collection for Studies of Lymph Cancer
Recruiting
1,295 enrolled
OLYMPIA-4
Phase 3 Recruiting
216 enrolled
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
132 enrolled
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Phase 1/2 Recruiting
940 enrolled 2 FDA
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Recruiting
2,000 enrolled
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 Recruiting
24 enrolled
Lumi-NHL
Phase 1/2 Recruiting
91 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
BRUIN-CLL-314
Phase 3 Recruiting
662 enrolled
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Phase 2 Recruiting
27 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
NexCAR19
Phase 2/3 Recruiting
40 enrolled
CAPTUR
Phase 2 Recruiting
720 enrolled
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Phase 2 Recruiting
49 enrolled
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Phase 1 Recruiting
46 enrolled
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Phase 1 Recruiting
180 enrolled
PALS
Phase NA Recruiting
110 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
121 enrolled
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Phase 2 Recruiting
28 enrolled
COSMIC
Recruiting
2,000 enrolled